Steel J L, Landsittel D, Calhoun B, Wieand S, Kingsley L A
University of Pittsburgh, School of Medicine, Department of Surgery, Thomas E. Starzl Transplant Institute, 3459 Fifth Avenue, 3459 Fifth Avenue, Montefiore 7 South, Pittsburgh, Pennsylvania 15213, USA.
AIDS Patient Care STDS. 2006 Aug;20(8):565-75. doi: 10.1089/apc.2006.20.565.
The aim of the study was a prospective assessment of the possible consequences of a diagnosis of lipodystrophy on health-related quality of life (HRQL) and depressive symptomatology in HIV-seropositive men who have sex with men. A standardized physical assessment for lipodystrophy was introduced within a prospective study in April 1999. Over a 2-year follow- up, 37 HIV-seropositive men who met the criteria for lipodystrophy were longitudinally compared to 92 HIV-seropositive men without lipodystrophy and 88 HIV-seronegative men on measures of HRQL and depression. A series of questionnaires, which included the Medical Outcomes Study Short-Form 36 (SF-36) and the Center for Epidemiological Studies-Depression (CES-D), were administered to assess HRQL and depression, respectively. SF-36 scores were summarized using the mental and physical components; CES-D results were reported as both dichotomous (with or with clinical depression) and continuous scores. Neither the mental nor physical components of the SF-36 showed any significant differences between patients with lipodystrophy versus HIV-seropositive patients without lipodystrophy. Similarly, lipodystrophy status was not significantly associated with either continuous depression scores or presence of clinical depression. However, consistent with previous results, HIV-seropositive men without lipodystrophy (compared to HIV-seronegative men) reported higher scores on both components of the SF-36 scales and both categorizations of the CES-D. The results of this study suggest that lipodystrophy does not negatively affect HRQL or depression, above and beyond, the diagnosis of HIV infection, although the impact of the severity of lipodystrophy on these conditions will require further study.
本研究的目的是对诊断为脂肪代谢障碍的男男性接触者中，与健康相关的生活质量（HRQL）和抑郁症状的可能后果进行前瞻性评估。1999年4月，在一项前瞻性研究中引入了标准化的脂肪代谢障碍身体评估。在2年的随访中，将37名符合脂肪代谢障碍标准的HIV血清阳性男性，与92名无脂肪代谢障碍的HIV血清阳性男性以及88名HIV血清阴性男性，在HRQL和抑郁测量指标上进行纵向比较。使用了一系列问卷，其中包括医学结局研究简表36（SF-36）和流行病学研究中心抑郁量表（CES-D），分别用于评估HRQL和抑郁情况。SF-36评分通过心理和生理成分进行汇总；CES-D结果以二分法（有或无临床抑郁）和连续评分两种方式报告。SF-36的心理和生理成分在有脂肪代谢障碍的患者与无脂肪代谢障碍的HIV血清阳性患者之间均未显示出任何显著差异。同样，脂肪代谢障碍状态与连续抑郁评分或临床抑郁的存在均无显著关联。然而，与先前结果一致，无脂肪代谢障碍的HIV血清阳性男性（与HIV血清阴性男性相比）在SF-36量表的两个成分以及CES-D的两种分类上得分均更高。本研究结果表明，脂肪代谢障碍除了HIV感染诊断之外，不会对HRQL或抑郁产生负面影响，尽管脂肪代谢障碍严重程度对这些状况的影响还需要进一步研究。
